ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in non-small cell lung cancer (NSCLC), including a Phase 3 clinical trial for treatment of patients with advanced or metastatic EGFRm NSCLC with exon 20 insertion mutations, as well as Phase 1b clinical trials to treat NSCLC patients with activating EGFRm, including P-loop and-alpha-c-helix compressing (PACC) mutations, and classical EGFRm NSCLC patients. It is also developing ARR-217, an antibody drug conjugate (ADC) for the treatment of gastrointestinal cancers; and ARR-002, ARR-421, and ARR-173 for solid tumors. The company has strategic collaborations with Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd., and Lepu Biopharma Co. Ltd. ArriVent BioPharma, Inc. was incorporated in 2021 and is based in Newtown Square, Pennsylvania.…
ArriVent BioPharma Reports Third Quarter 2026 Financial Results
ArriVent BioPharma (NASDAQ: AVBP) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 77 employees.
The shares were at 10.52 USD on 20 November 2026, down 41.7% over 52 weeks. Its 52-week range is 10.33 USD to 35.83 USD: the price is 70.6% below the high and 1.8% above the low.
Its market capitalisation is 544.13M USD.
ArriVent BioPharma reports return on equity of -54.1%.
It holds more cash than debt, a net cash position of 392.97M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 26.20 USD is 149.0% above the current price. The next earnings report is expected on 8 March 2027.